Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20860928 | 0.83 | ADORA2A (0.79) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL11780284 | 0.81 | ACHE (0.65) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL6111135 | 0.80 | L3MBTL1 (0.52) | RAB9AMEN1KMT2ANPC1LMNA | |
| SCHEMBL11810896 | 0.80 | L3MBTL1 (0.52) | RAB9AMEN1KMT2ANPC1LMNA | |
| SCHEMBL672647 | 0.79 | RAB9A (0.61) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL8486932 | 0.79 | HRH4 (0.57) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL7708521 | 0.79 | MEN1 (0.67) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL3898780 | 0.78 | ADORA2A (0.51) | MEN1KMT2ALMNAADORA2AADORA1 | |
| SCHEMBL15025989 | 0.78 | L3MBTL1 (0.50) | RAB9AMEN1KMT2ANPC1LMNA | |
| SCHEMBL13231717 | 0.78 | L3MBTL1 (0.50) | RAB9AMEN1KMT2ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073361-B | Rosin diterpenoid compound and preparation method and application thereof | 广东药科大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-115073361-A | Rosin diterpenoid compound and preparation method and application thereof | 广东药科大学 | 2022-09-20 | — | — | CN | disclosed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| CN-110325516-A | HETEROARYL COMPOUNDS AND THEIR USE | 米尼奥尔克斯治疗有限公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-105367503-A | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS INC | 2016-03-02 | — | — | CN | disclosed |
| CN-101902911-B | Heteroaryl compounds and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2015-12-16 | — | — | CN | disclosed |
| EP-2421538-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7989465-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7982036-B2 | 4,6-disubstitued pyrimidines useful as kinase inhibitors | AVILA THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| EP-1363638-A2 | USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | Synaptic Pharmaceutical Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002060392-A2 | USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-08-08 | — | — | WO | disclosed |
| EP-0274356-B1 | VATTABLE 2-ARYL-4,6-DIAMINOPYRIMIDINE | CIBA-GEIGY AG (CH) | 1990-05-16 | — | — | EP | disclosed |
| US-4845220-A | Vattable 2-aryl-4,6-diaminopyrimidines | CIBA-GEIGY CORPORATION | 1989-07-04 | — | — | US | disclosed |
| EP-0274356-A1 | Vattable 2-aryl-4,6-diaminopyrimidine | CIBA-GEIGY AG (CH) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224432-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | RAB9A 580/4885SMN1; SMN2 2352/4885MEN1 606/4885 |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | BMI1, BRPF3, BAZ2A | RAB9A 2804/4885SMN1; SMN2 2600/4885MEN1 1574/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | RAB9A 3130/4885SMN1; SMN2 1308/4885MEN1 4128/4885 |
| US-20110230494-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | RAB9A 580/4885SMN1; SMN2 2352/4885MEN1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.